Table 2.
Cardiac magnetic resonance-derived parameters at day 7 and day 45 follow-up
| 20-Min I/R | 25-Min I/R | 30-Min I/R | 35-Min I/R | 40-Min I/R | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vehicle | Metopr | p value | Vehicle | Metopr | p value | Vehicle | Metopr | p value | Vehicle | Metopr | p value | Vehicle | Metopr | p value | |
| MDCT | |||||||||||||||
| N | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 12 | 12 | |||||
| AAR (% LV) | 30.9 [28–36] | 33.4 [28–38] | 0.73 | 26.9 [23–35] | 31.7 [29–38] | 0.22 | 26.2 [22–32] | 26 [24–30] | 0.84 | 30 [28–32] | 32 [30–33] | 0.06 | 32.7 [29–34] | 28.5 [27–31] | 0.06 |
| Day 7 CMR | |||||||||||||||
| N | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 11 | 11 | |||||
| IS (% AAR) | 6.2 [0–10] | 1.4 [0–4] | 0.4 | 0 [0–35] | 9.4 [3–33] | 0.55 | 68.3 [59–86] | 45 [28–54] | 0.01 | 72.7 [70–87] | 45 [28–58] | 0.01 | 95 [88–100] | 72 [65–82] | 0.001 |
| IS (% LV) | 1.8 [0–4] | 0.5 [0–1] | 0.5 | 0 [0–12] | 3 [1–13] | 0.6 | 19 [14–26] | 16 [8–18] | 0.3 | 21 [19–26] | 14 [7–18] | 0.01 | 29.6 [27–33] | 22.6 [18–23] | > 0.001 |
| MVO (g) | 0 [0–0] | 0 [0–0] | 0.9 | 0 [0–0] | 0 [0–0] | 0.9 | 0 [0–0] | 0 [0–0] | 0.9 | 0 [0–2] | 0 [0–0] | 0.9 | 0.1 [0–1] | 0 [0–0] | 0.2 |
| Day 45 CMR | |||||||||||||||
| N | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 9 | 10 | |||||
| LVEF (%) | 55.3 [49–59] | 55.1 [50.78] | 0.9 | 52.4 [50–59] | 55.1 [50–60] | 0.9 | 43.6 [31–45] | 45.5 [38–47] | 0.4 | 40.4 [30–44] | 44.9 [39–53] | 0.3 | 32.6 [31–34] | 35.7 [33–45] | 0.02 |
| 45-Min I/R | 50-Min I/R | 60-Min I/R | Pooled cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vehicle | Metopr | p value | Vehicle | Metopr | p value | Vehicle | Metopr | p value | Vehicle | Metopr | p value | |
| MDCT | ||||||||||||
| N | 12 | 12 | 12 | 12 | 5 | 5 | 61 | 61 | ||||
| AAR (% LV) | 31.5 [29–36] | 31 [29–33] | 0.48 | 35.7 [32–38] | 35.1 [31–38] | 0.55 | 38.2 [33–41] | 39.4 [35–42] | 0.7 | 31.9 [29–36] | 31.3 [28–35] | 0.8 |
| Day 7 CMR | ||||||||||||
| N | 11 | 12 | 10 | 11 | 5 | 5 | 57 | 59 | ||||
| IS (% AAR) | 93 [91–96] | 82 [72–89] | 0.002 | 99.4 [95–100] | 83 [78–91] | 0.001 | 100 [96–100] | 99.8 [84–100] | 0.3 | 91.7 [70–99] | 72.5 [40–86] | < 0.001 |
| IS (% LV) | 30.7 [28–34] | 23.7 [21–25] | < 0.001 | 35.4 [34–36] | 28 [26–32] | < 0.001 | 40.7 [35–41] | 36 [33–38] | 0.22 | 29.5 [20–34] | 22.6 [13–27] | 0.001 |
| MVO (g) | 1.6 [1–3] | 0.6 [0–1] | 0.01 | 0.4 [0–4] | 0 [0–1] | 0.06 | 0.6 [0–1] | 3 [0–4] | 0.9 | 0 [0–1] | 0 [0–0] | 0.09 |
| Day 45 CMR | ||||||||||||
| N | 10 | 12 | 6 | 9 | 4 | 4 | 45 | 51 | ||||
| LVEF (%) | 28.5 [27–36] | 36.7 [33–44] | 0.005 | 27.8 [26–34] | 35.2 [33–37] | 0.1 | 25.7 [21–32] | 33.6 [31–35] | 0.1 | 32.8 [29–43] | 40 [34–49] | 0.001 |
Data are shown as median [interquartile range]
LVEF left ventricular ejection fraction, MAR myocardial area at risk, metopr metoprolol, MVO microvascular obstruction